Q-omics provides the consensus-scored PTPN1 profile across patient tissues and cancer cell-line models. PTPN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PTPN1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PTPN1 protein abundance shows 21,453 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where PTPN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN1 survival associations across molecular data types. PTPN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN1 RNA expression–survival associations across cancer types. High PTPN1 expression shows unfavorable associations in UVM, LIHC, LAML, OV, LGG and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PTPN1 RNA expression.
This table summarizes PTPN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN1 shows lower tumor expression in LUAD and higher tumor expression in HNSC, KIRP, KIRC, LIHC and COAD. The HNSC box plot shows higher PTPN1 RNA expression in tumor versus normal tissue (log2 FC = +1.234, t-test p < 0.001).
This table shows molecular features associated with PTPN1 in patient tissues and cancer cell lines. In patient samples, PTPN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
